- Home
- UTHR vs SNN Comparison
UTHR vs SNN Comparison
Compare UTHR & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- SNN
- Stock Information
- Founded
- UTHR 1996
- SNN 1856
- Country
- UTHR United States
- SNN United Kingdom
- Employees
- UTHR N/A
- SNN N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- UTHR Health Care
- SNN Health Care
- Exchange
- UTHR Nasdaq
- SNN Nasdaq
- Market Cap
- UTHR 14.4B
- SNN 12.3B
- IPO Year
- UTHR 1999
- SNN 1999
- Fundamental
- Price
- UTHR $284.73
- SNN $25.93
- Analyst Decision
- UTHR Buy
- SNN Hold
- Analyst Count
- UTHR 12
- SNN 3
- Target Price
- UTHR $388.25
- SNN $27.00
- AVG Volume (30 Days)
- UTHR 499.4K
- SNN 1.2M
- Earning Date
- UTHR 04-30-2025
- SNN 02-25-2025
- Dividend Yield
- UTHR N/A
- SNN 2.89%
- EPS Growth
- UTHR 24.38
- SNN 56.15
- EPS
- UTHR 24.64
- SNN 0.47
- Revenue
- UTHR $2,877,400,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- UTHR $11.52
- SNN $6.42
- Revenue Next Year
- UTHR $6.08
- SNN $5.03
- P/E Ratio
- UTHR $11.56
- SNN $27.69
- Revenue Growth
- UTHR 23.63
- SNN 4.70
- 52 Week Low
- UTHR $233.28
- SNN $23.65
- 52 Week High
- UTHR $417.82
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- UTHR 37.49
- SNN 41.26
- Support Level
- UTHR $266.98
- SNN $25.63
- Resistance Level
- UTHR $288.54
- SNN $26.32
- Average True Range (ATR)
- UTHR 14.43
- SNN 0.74
- MACD
- UTHR -0.15
- SNN -0.13
- Stochastic Oscillator
- UTHR 38.23
- SNN 41.06
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.